AC Immune SA
AC Immune SA

AC Immune SA

Biotechnology
WebsiteInvestor RelationsSEC
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

$277.3M

Market Cap • 10/2/2026

2003

(23 years)

Founded

2016

(10 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Switzerland

Switzerland

Country

Valuation

P/B

6,4

P/S

12,8

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,4

EPS

—

Market Cap

Market Cap

277,3M

EV

189,2M

EV/Revenue

8,7

EV/EBITDA

-3,6

EV/EBIT

-3,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-556,9M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

265%

Capex/Revenue

3,4%

Capex/D&A

25,9%

Capex/OCF

-1,2%

SBC/OCF

—

% PPE

4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

52,1%

CAGR Op. Income 5Y

-8,1%

CAGR Net Income 5Y

-7,9%

CAGR EPS 5Y

-13,6%

CAGR OCF 5Y

-3,7%

Leverage

N.D./EBITDA

1,7

Debt/Equity

0%

Current Ratio

0,9

Quick Ratio

0,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium